TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Post-Operative Crohn's Disease Endoscopic Recurrence "POCER" Study: Endoscopic Guided Therapeutic Intervention & Determination of Cause
Brief Summary: This randomised, controlled study aims to evaluate the impact of endoscopic assessment, and adjustment of therapy, after surgery in patients with Crohn's disease. The primary endpoint is the severity of endoscopic recurrence. In addition, tissue will be collected for microbiological and immunological analysis.


Options:
A: Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): N/A
B: Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): N/A
C: Arm Label: DB Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo eow; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: OL Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): DB Adalimumab 40 mg eow, OL Adalimumab 40 mg eow | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo eow
D: Arm Label: Active arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: endoscopy | Arm Label: Standard care arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: endoscopy; Assigned to Arm(s): Active arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Post-Operative Crohn's Disease Endoscopic Recurrence "POCER" Study: Endoscopic Guided Therapeutic Intervention & Determination of Cause
Brief Summary: This randomised, controlled study aims to evaluate the impact of endoscopic assessment, and adjustment of therapy, after surgery in patients with Crohn's disease. The primary endpoint is the severity of endoscopic recurrence. In addition, tissue will be collected for microbiological and immunological analysis.


Options:
A: Arm Label: Metronidazole + Azathioprine.; Type: EXPERIMENTAL; Interventions: Drug: Metronidazole, Drug: Azathioprine | Arm Label: Metronidazole + Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metronidazole, Drug: Adalimumab | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Metronidazole + Azathioprine. | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Metronidazole + Adalimumab | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Metronidazole + Azathioprine. | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Metronidazole + Adalimumab
B: Arm Label: Azathioprine; Type: EXPERIMENTAL; Interventions: Drug: Azathioprine, Drug: Mesalazine placebo | Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine, Drug: Azathioprine placebo | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Azathioprine | Intervention Type: DRUG; Name: Mesalazine; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Azathioprine placebo; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Mesalazine placebo; Assigned to Arm(s): Azathioprine
C: Arm Label: Active arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: endoscopy | Arm Label: Standard care arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: endoscopy; Assigned to Arm(s): Active arm
D: Arm Label: Systematic azathioprine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine, Procedure: Ileocolonoscopy, Procedure: Small bowel follow trough | Arm Label: Endoscopy-driven azathioprine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine in case of endoscopic recurrence, Procedure: Ileocolonoscopy, Procedure: Small bowel follow trough | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Systematic azathioprine group | Intervention Type: DRUG; Name: Azathioprine in case of endoscopic recurrence; Assigned to Arm(s): Endoscopy-driven azathioprine group | Intervention Type: PROCEDURE; Name: Ileocolonoscopy; Assigned to Arm(s): Endoscopy-driven azathioprine group, Systematic azathioprine group | Intervention Type: PROCEDURE; Name: Small bowel follow trough; Assigned to Arm(s): Endoscopy-driven azathioprine group, Systematic azathioprine group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preoperative Methylprednisolone in Endovascular Aortic Repair - a Randomized Double Blind Placebo Controlled Clinical Trial
Brief Summary: The purpose of this study is to attenuate the systemic inflammatory response after Endovascular repair of abdominal aortic aneurysms, by administration of a single preoperative dosage of Methylprednisolone.


Options:
A: Arm Label: Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline | Arm Label: Hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): Normal Saline
B: Arm Label: Dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Control
C: Arm Label: Single dose steroid; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone (IVMP) | Arm Label: Two Dose steroid; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone (two doses IVMP) | Intervention Type: DRUG; Name: methylprednisolone (IVMP); Assigned to Arm(s): Single dose steroid | Intervention Type: DRUG; Name: methylprednisolone (two doses IVMP); Assigned to Arm(s): Two Dose steroid
D: Arm Label: Methylprednisolone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylprednisolone | Arm Label: Physiological Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Physiological Saline | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Methylprednisolone | Intervention Type: DRUG; Name: Physiological Saline; Assigned to Arm(s): Physiological Saline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Cross-over, Open-labelled Study Evaluating the Acceptance of Test Catheters Compared to SpeediCath Catheters
Brief Summary: The purpose of this study is to evaluate that the test catheter is no less accepted than the SpeediCath (SC) catheter.


Options:
A: Arm Label: Single-use catheter; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Single-use catheter, Diagnostic Test: Urine culture | Arm Label: Reused catheter with 0.5% benzalkonium chloride; Type: EXPERIMENTAL; Interventions: Procedure: Reused catheter, Diagnostic Test: Urine culture | Arm Label: Reused catheter with soap and water; Type: EXPERIMENTAL; Interventions: Procedure: Reused catheter, Diagnostic Test: Urine culture | Intervention Type: PROCEDURE; Name: Single-use catheter; Assigned to Arm(s): Single-use catheter | Intervention Type: PROCEDURE; Name: Reused catheter; Assigned to Arm(s): Reused catheter with 0.5% benzalkonium chloride, Reused catheter with soap and water | Intervention Type: DIAGNOSTIC_TEST; Name: Urine culture; Assigned to Arm(s): Reused catheter with 0.5% benzalkonium chloride, Reused catheter with soap and water, Single-use catheter
B: Arm Label: test intermittent catheter; Type: EXPERIMENTAL; Interventions: Device: test intermittent catheter | Arm Label: intermittent catheter; Type: EXPERIMENTAL; Interventions: Device: Intermittent catheterization | Intervention Type: DEVICE; Name: test intermittent catheter; Assigned to Arm(s): test intermittent catheter | Intervention Type: DEVICE; Name: Intermittent catheterization; Assigned to Arm(s): intermittent catheter
C: Arm Label: SpeediCath catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: SpeediCath | Arm Label: Test product; Type: EXPERIMENTAL; Interventions: Device: Test Catheter - SpeediCath Compact Male | Intervention Type: DEVICE; Name: Test Catheter - SpeediCath Compact Male; Assigned to Arm(s): Test product | Intervention Type: DEVICE; Name: SpeediCath; Assigned to Arm(s): SpeediCath catheter
D: Arm Label: Compact catheter; Type: EXPERIMENTAL; Interventions: Device: SpeediCath Compact | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard care | Intervention Type: DEVICE; Name: SpeediCath Compact; Assigned to Arm(s): Compact catheter | Intervention Type: DEVICE; Name: Standard care; Assigned to Arm(s): Standard Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Controlled Trial of Home Mechanical Ventilation in Hypercapnic Chronic Obstructive Pulmonary Disease Patients Post Acute Hypercapnic Exacerbation
Brief Summary: This study is designed to investigate the effect of home mechanical ventilation (HMV) in patients with severe chronic obstructive pulmonary disease (COPD). The purpose of the trial is to test the hypothesis that HMV and longterm oxygen therapy (LTOT) increases admission free survival compared with LTOT alone. More specifically, compared with LTOT, HMV and LTOT reduces hospital re-admission in COPD patients who remain persistently hypercapnic following an acute exacerbation requiring non-invasive ventilation (NIV).


Options:
A: Arm Label: Long term oxygen therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Long term oxygen therapy | Arm Label: Home mechanical ventilation; Type: EXPERIMENTAL; Interventions: Device: Home mechanical ventilation | Intervention Type: DEVICE; Name: Home mechanical ventilation; Assigned to Arm(s): Home mechanical ventilation | Intervention Type: DEVICE; Name: Long term oxygen therapy; Assigned to Arm(s): Long term oxygen therapy
B: Arm Label: LTNIV group; Type: EXPERIMENTAL; Interventions: Device: LTNIV | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: LTNIV; Assigned to Arm(s): LTNIV group
C: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
D: Arm Label: Active Treatment; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous Positive Airway Pressure (CPAP) Treatment | Arm Label: Sham/Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham CPAP device - CPAP device with pressure delivered <1 cm H20 | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP) Treatment; Assigned to Arm(s): Active Treatment | Intervention Type: DEVICE; Name: Sham CPAP device - CPAP device with pressure delivered <1 cm H20; Assigned to Arm(s): Sham/Placebo Treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
Brief Summary: A transient ischemic attack (TIA) is a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. An ischemic stroke is a cerebral infarction. In POINT, eligibility is limited to brain TIAs and to minor ischemic strokes (with an NIH Stroke Scale \[NIHSS\] score less than or equal to 3).

TIAs are common \[25\], and are often harbingers of disabling strokes. Approximately 250,000-350,000 TIAs are diagnosed each year in the US. Given median survival of more than 8 years \[32\], there are approximately 2.4 million TIA survivors. In a national survey, one in fifteen of those over 65 years old reported a history of TIA \[33\], which is equivalent to a prevalence of 2.3 million in older Americans. Based on the prevalence of undiagnosed transient neurological events, the true incidence of TIA may be twice as high as the rates of diagnosis \[33\]. Based on our review of the National Inpatient Sample for 1997-2003, there were an average of 200,000 hospital admissions for TIA each year, with annual charges climbing quickly in the period to $2.6 billion in 2003.

Composite endpoint of new ischemic vascular events: ischemic stroke, myocardial infarction or ischemic vascular death at 90 days.


Options:
A: Arm Label: clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): clopidogrel | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo
C: Intervention Type: DRUG; Name: Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ASA 100 mg qd; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
Brief Summary: A transient ischemic attack (TIA) is a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. An ischemic stroke is a cerebral infarction. In POINT, eligibility is limited to brain TIAs and to minor ischemic strokes (with an NIH Stroke Scale \[NIHSS\] score less than or equal to 3).

TIAs are common \[25\], and are often harbingers of disabling strokes. Approximately 250,000-350,000 TIAs are diagnosed each year in the US. Given median survival of more than 8 years \[32\], there are approximately 2.4 million TIA survivors. In a national survey, one in fifteen of those over 65 years old reported a history of TIA \[33\], which is equivalent to a prevalence of 2.3 million in older Americans. Based on the prevalence of undiagnosed transient neurological events, the true incidence of TIA may be twice as high as the rates of diagnosis \[33\]. Based on our review of the National Inpatient Sample for 1997-2003, there were an average of 200,000 hospital admissions for TIA each year, with annual charges climbing quickly in the period to $2.6 billion in 2003.

Composite endpoint of new ischemic vascular events: ischemic stroke, myocardial infarction or ischemic vascular death at 90 days.


Options:
A: Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A
B: Arm Label: Aggrenox Capsule; Type: OTHER; Interventions: Drug: Aggrenox capsule | Arm Label: Acetylsalicylic Acid (ASA) 81 mg Tablet; Type: OTHER; Interventions: Other: Acetylsalicylic Acid (ASA) | Intervention Type: DRUG; Name: Aggrenox capsule; Assigned to Arm(s): Aggrenox Capsule | Intervention Type: OTHER; Name: Acetylsalicylic Acid (ASA); Assigned to Arm(s): Acetylsalicylic Acid (ASA) 81 mg Tablet
C: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A
D: Arm Label: clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): clopidogrel | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Red Cell Storage Duration Study
Brief Summary: The RECESS study will compare the effects of transfusing red blood cell units stored \<= 10 days vs. red blood cell units stored \>= 21 days, in patients who are undergoing complex cardiac surgery and are likely to need a red blood cell transfusion. The primary hypothesis is that there is a clinically important difference between the effects of shorter-storage red cell units and longer-storage red cell units on clinical outcomes and mortality risk.


Options:
A: Arm Label: Shorter-storage red blood cell units; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell units stored <= 10 days | Arm Label: Longer-storage red blood cell units; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell units stored >= 21 days | Intervention Type: BIOLOGICAL; Name: Red blood cell units stored <= 10 days; Assigned to Arm(s): Shorter-storage red blood cell units | Intervention Type: BIOLOGICAL; Name: Red blood cell units stored >= 21 days; Assigned to Arm(s): Longer-storage red blood cell units
B: Arm Label: Fresh transfusion; Type: OTHER; Interventions: Procedure: Fresh transfusion, Procedure: Old transfusion | Arm Label: Old transfusion; Type: EXPERIMENTAL; Interventions: Procedure: Fresh transfusion, Procedure: Old transfusion | Intervention Type: PROCEDURE; Name: Fresh transfusion; Assigned to Arm(s): Fresh transfusion, Old transfusion | Intervention Type: PROCEDURE; Name: Old transfusion; Assigned to Arm(s): Fresh transfusion, Old transfusion
C: Arm Label: Standard of care; Type: ACTIVE_COMPARATOR; Interventions: Other: Blood transfusion | Arm Label: Arm B; Type: OTHER; Interventions: Other: Blood transfusion | Intervention Type: OTHER; Name: Blood transfusion; Assigned to Arm(s): Arm B, Standard of care
D: Arm Label: Fresh blood, then aged blood; Type: EXPERIMENTAL; Interventions: Biological: Fresh blood, Biological: Aged blood | Intervention Type: BIOLOGICAL; Name: Fresh blood; Assigned to Arm(s): Fresh blood, then aged blood | Intervention Type: BIOLOGICAL; Name: Aged blood; Assigned to Arm(s): Fresh blood, then aged blood

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Red Cell Storage Duration Study
Brief Summary: The RECESS study will compare the effects of transfusing red blood cell units stored \<= 10 days vs. red blood cell units stored \>= 21 days, in patients who are undergoing complex cardiac surgery and are likely to need a red blood cell transfusion. The primary hypothesis is that there is a clinically important difference between the effects of shorter-storage red cell units and longer-storage red cell units on clinical outcomes and mortality risk.


Options:
A: Arm Label: Shorter-storage red blood cell units; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell units stored <= 10 days | Arm Label: Longer-storage red blood cell units; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell units stored >= 21 days | Intervention Type: BIOLOGICAL; Name: Red blood cell units stored <= 10 days; Assigned to Arm(s): Shorter-storage red blood cell units | Intervention Type: BIOLOGICAL; Name: Red blood cell units stored >= 21 days; Assigned to Arm(s): Longer-storage red blood cell units
B: Arm Label: Single-Unit Blood Transfusion Protocol; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood Transfusion | Arm Label: Multiple-Unit Blood Transfusion Protocol; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood Transfusion | Intervention Type: BIOLOGICAL; Name: Blood Transfusion; Assigned to Arm(s): Multiple-Unit Blood Transfusion Protocol, Single-Unit Blood Transfusion Protocol
C: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy
D: Arm Label: Low transfusion trigger; Type: ACTIVE_COMPARATOR; Interventions: Biological: red blood cell transfusion | Arm Label: High transfusion trigger; Type: ACTIVE_COMPARATOR; Interventions: Biological: red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: red blood cell transfusion; Assigned to Arm(s): High transfusion trigger, Low transfusion trigger

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Red Cell Storage Duration Study
Brief Summary: The RECESS study will compare the effects of transfusing red blood cell units stored \<= 10 days vs. red blood cell units stored \>= 21 days, in patients who are undergoing complex cardiac surgery and are likely to need a red blood cell transfusion. The primary hypothesis is that there is a clinically important difference between the effects of shorter-storage red cell units and longer-storage red cell units on clinical outcomes and mortality risk.


Options:
A: Arm Label: Shorter-storage red blood cell units; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell units stored <= 10 days | Arm Label: Longer-storage red blood cell units; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell units stored >= 21 days | Intervention Type: BIOLOGICAL; Name: Red blood cell units stored <= 10 days; Assigned to Arm(s): Shorter-storage red blood cell units | Intervention Type: BIOLOGICAL; Name: Red blood cell units stored >= 21 days; Assigned to Arm(s): Longer-storage red blood cell units
B: Arm Label: Fresh transfusion; Type: OTHER; Interventions: Procedure: Fresh transfusion, Procedure: Old transfusion | Arm Label: Old transfusion; Type: EXPERIMENTAL; Interventions: Procedure: Fresh transfusion, Procedure: Old transfusion | Intervention Type: PROCEDURE; Name: Fresh transfusion; Assigned to Arm(s): Fresh transfusion, Old transfusion | Intervention Type: PROCEDURE; Name: Old transfusion; Assigned to Arm(s): Fresh transfusion, Old transfusion
C: Arm Label: Short storage; Type: EXPERIMENTAL; Interventions: Biological: Blood transfusion | Arm Label: Long storage arm; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood transfusion | Intervention Type: BIOLOGICAL; Name: Blood transfusion; Assigned to Arm(s): Long storage arm, Short storage
D: Arm Label: bCBT/Direct Referral; Type: EXPERIMENTAL; Interventions: Behavioral: bCBT | Arm Label: Enhanced Usual Care (EUC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: bCBT; Assigned to Arm(s): bCBT/Direct Referral

Answer: A